| Primary |
| Myocardial Infarction |
38.7% |
| Hypertension |
12.9% |
| Gastritis |
9.7% |
| Acute Myocardial Infarction |
6.5% |
| Diabetes Mellitus |
6.5% |
| Pulmonary Embolism |
6.5% |
| Anuria |
3.2% |
| Depression |
3.2% |
| Ischaemia |
3.2% |
| Platelet Aggregation |
3.2% |
| Pneumonia |
3.2% |
| Ulcer |
3.2% |
|
| Intracardiac Thrombus |
40.0% |
| Muscle Haemorrhage |
20.0% |
| Pancytopenia |
20.0% |
| Red Blood Cell Count Decreased |
20.0% |
|
| Secondary |
| Acute Myocardial Infarction |
20.4% |
| Myocardial Infarction |
16.3% |
| Pulmonary Embolism |
9.6% |
| Anticoagulant Therapy |
5.8% |
| Percutaneous Coronary Intervention |
5.8% |
| Cardio-respiratory Arrest |
4.4% |
| Deep Vein Thrombosis |
4.4% |
| Kawasaki's Disease |
3.9% |
| Product Used For Unknown Indication |
3.9% |
| Acute Coronary Syndrome |
3.3% |
| Hypertension |
3.3% |
| Peripheral Artery Thrombosis |
3.3% |
| Atrial Fibrillation |
2.8% |
| Drug Use For Unknown Indication |
2.5% |
| Gastritis |
2.5% |
| Thrombolysis |
1.9% |
| Diabetes Mellitus |
1.7% |
| Intracardiac Thrombus |
1.7% |
| Cerebrovascular Accident Prophylaxis |
1.4% |
| Thrombosis Prophylaxis |
1.4% |
|
| Pulmonary Embolism |
10.9% |
| Intracardiac Thrombus |
9.4% |
| Coronary Revascularisation |
6.3% |
| Death |
6.3% |
| Haemorrhage |
6.3% |
| Renal Failure Acute |
6.3% |
| Skin Haemorrhage |
6.3% |
| Multi-organ Failure |
4.7% |
| Pancytopenia |
4.7% |
| Red Blood Cell Count Decreased |
4.7% |
| Thrombosis |
4.7% |
| Vascular Operation |
4.7% |
| Cardiac Tamponade |
3.1% |
| Drug Ineffective |
3.1% |
| Hypotension |
3.1% |
| Pain In Extremity |
3.1% |
| Pneumonia |
3.1% |
| Sensory Loss |
3.1% |
| Thrombocytopenia |
3.1% |
| Tinnitus |
3.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
21.4% |
| Pulmonary Embolism |
7.6% |
| Rheumatoid Arthritis |
7.6% |
| Anticoagulant Therapy |
6.9% |
| Percutaneous Coronary Intervention |
6.9% |
| Deep Vein Thrombosis |
5.3% |
| Angina Unstable |
5.0% |
| Atrial Fibrillation |
5.0% |
| Drug Use For Unknown Indication |
5.0% |
| Acute Myocardial Infarction |
4.2% |
| Cerebrovascular Accident Prophylaxis |
4.2% |
| Immunosuppression |
4.2% |
| Myocardial Infarction |
4.2% |
| Thrombosis Prophylaxis |
3.1% |
| Antiphospholipid Syndrome |
1.9% |
| Alpha Haemolytic Streptococcal Infection |
1.5% |
| Factor Viii Deficiency |
1.5% |
| Hypertension |
1.5% |
| Tuberculosis |
1.5% |
| Type 2 Diabetes Mellitus |
1.5% |
|
| Thrombocytopenia |
21.1% |
| Death |
15.8% |
| Off Label Use |
8.8% |
| International Normalised Ratio Increased |
7.0% |
| Myocardial Infarction |
7.0% |
| Catheter Thrombosis |
3.5% |
| Coagulation Time Prolonged |
3.5% |
| Coronary Artery Thrombosis |
3.5% |
| Hepatocellular Injury |
3.5% |
| Occult Blood Positive |
3.5% |
| Paraesthesia |
3.5% |
| Pulmonary Embolism |
3.5% |
| Rheumatoid Arthritis |
3.5% |
| Acute Generalised Exanthematous Pustulosis |
1.8% |
| Acute Myocardial Infarction |
1.8% |
| Cardiac Failure Congestive |
1.8% |
| Catheter Related Complication |
1.8% |
| Cerebral Infarction |
1.8% |
| Cerebrovascular Accident |
1.8% |
| Coronary Artery Disease |
1.8% |
|
| Interacting |
| Infection Prophylaxis |
27.6% |
| Dehydration |
13.8% |
| Haemodialysis |
13.8% |
| Oedema |
13.8% |
| Atrial Fibrillation |
10.3% |
| Cerebrovascular Accident Prophylaxis |
6.9% |
| Cerebrovascular Accident |
3.4% |
| Dialysis |
3.4% |
| Ischaemic Heart Disease Prophylaxis |
3.4% |
| Product Used For Unknown Indication |
3.4% |
|
| Urinary Tract Infection |
50.0% |
| Procedural Haemorrhage |
25.0% |
| Shock Haemorrhagic |
25.0% |
|
